Pharmacokinetics of rolapitant in patients with mild to moderate hepatic impairment versus healthy matched controls: A phase I, open-label, parallel group, single dose study

Trial Profile

Pharmacokinetics of rolapitant in patients with mild to moderate hepatic impairment versus healthy matched controls: A phase I, open-label, parallel group, single dose study

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Rolapitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Jan 2018 New trial record
    • 12 Jan 2018 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top